Actinomycosis medical therapy

Actinomycosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Actinomycosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Actinomycosis medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Actinomycosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Actinomycosis medical therapy
CDC on Actinomycosis medical therapy
Actinomycosis medical therapy in the news
Blogs on Actinomycosis medical therapy
to Hospitals Treating Actinomycosis
Risk calculators and risk factors for Actinomycosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pharmacotherapy

• In vitro susceptible to:

  • Penicillin
  • Chloramphenicol
  • The tetracyclines
  • Erythromycin
  • Clindamycin
  • Imipenem
  • Streptomycin
  • The cephalosporins

    • Prolonged treatment (6-12 months)

References

Template:Bacterial diseases
Template:SIB de:Aktinomykose gl:Actinomicose hr:Aktinomikoza nl:Actinomycose sr:Актиномикоза fi:Aktinomykoosi uk:Актиномікоз